CTI BioPharma (NASDAQ:CTIC) Stock Price Passes Above Two Hundred Day Moving Average of $0.87

CTI BioPharma Corp (NASDAQ:CTIC) passed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $0.87 and traded as high as $0.83. CTI BioPharma shares last traded at $0.81, with a volume of 28,533 shares.

The stock’s fifty day moving average price is $0.70 and its 200 day moving average price is $0.87. The company has a quick ratio of 3.15, a current ratio of 3.15 and a debt-to-equity ratio of 0.20.

CTI BioPharma (NASDAQ:CTIC) last announced its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($0.19) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.19). The company had revenue of $0.42 million during the quarter. CTI BioPharma had a negative net margin of 225.01% and a negative return on equity of 77.77%.

Hedge funds and other institutional investors have recently modified their holdings of the company. SG Americas Securities LLC lifted its stake in CTI BioPharma by 44.0% in the 2nd quarter. SG Americas Securities LLC now owns 56,132 shares of the biopharmaceutical company’s stock worth $48,000 after purchasing an additional 17,163 shares in the last quarter. Jane Street Group LLC acquired a new position in shares of CTI BioPharma during the 2nd quarter worth approximately $119,000. Fosun International Ltd grew its position in shares of CTI BioPharma by 52.9% in the second quarter. Fosun International Ltd now owns 459,274 shares of the biopharmaceutical company’s stock valued at $390,000 after purchasing an additional 158,846 shares in the last quarter. Deutsche Bank AG grew its position in shares of CTI BioPharma by 220.7% in the fourth quarter. Deutsche Bank AG now owns 367,717 shares of the biopharmaceutical company’s stock valued at $269,000 after purchasing an additional 253,060 shares in the last quarter. Finally, Renaissance Technologies LLC increased its holdings in shares of CTI BioPharma by 24.5% in the second quarter. Renaissance Technologies LLC now owns 1,596,587 shares of the biopharmaceutical company’s stock valued at $1,372,000 after purchasing an additional 314,235 shares during the last quarter. Institutional investors and hedge funds own 47.04% of the company’s stock.

CTI BioPharma Company Profile (NASDAQ:CTIC)

CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally. It develops PIXUVRI, a novel aza-anthracenedione for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma; and pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R, which is in Phase III clinical trials for the treatment of adult patients with myelofibrosis.

Featured Article: Earnings Per Share

Receive News & Ratings for CTI BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CTI BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.